Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $156M (up 7.5% year over year) with net income of −$722M.
Q1 2026 key financials · XBRL
- Revenue
- $156M
- +7.5% YoY
- Net income
- −$722M
- −2255762.5% YoY
- Operating margin
- -448.6%
- EPS (diluted)
- −$2.98
Source: XBRL data from the BIOCRYST PHARMACEUTICALS INC (BCRX) Q1 2026 10-Q on SEC EDGAR. USD.
BIOCRYST PHARMACEUTICALS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Navenibart licensing: $70.0M upfront consideration, up to $275.0M milestone payments
- $400.0M Blackstone term loans funded merger cash consideration, maturing January 23, 2031
- Oral-pellet ORLADEYO fulfillment delayed by manufacturing issue, potential revenue impact under evaluation
Risk Factors
- Sustained profitability risk: 2025 marked first annual U.S. GAAP net income, but profitability remains unproven
- Commercialization risk: ORLADEYO revenues subject to royalties payable to RPI and OMERS
- Market risk: Patient and physician acceptance, reimbursement levels, and competition could undermine projected revenues
- Execution risk: Incorrect capital-allocation forecasts could disrupt operational and budget plans
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BIOCRYST PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.